Featured Story

  • Acorda's inhaled levodopa shows promise in Phase II trials

    Acorda Therapeutics moved a step closer to collecting the payoff from its $525 million acquisition of Civitas, maker of an inhaled levodopa, in the scramble to deliver an improved formulation of the standard Parkinson's med. The conventional oral formulation suffers from unpredictable absorption in the bloodstream and a wearing-off effect after about 5 years.

Cynapsus' sublingual Parkinson's med for "off" episodes progresses to PhIII

Cynapsus kicked off patient enrollment in its Phase III clinical trial of sublingual apomorphine for Parkinson's patients who stop responding to levodopa.

OptiNose heralds late-stage clinical success for nasal anti-inflammatory

Pennsylvania-based OptiNose, the creator of a bi-directional device for nasal medications, garnered positive results in a late-stage trial for its nasal polyp treatment. The company adds the anti-inflammatory treatment to its clinical lineup of migraine and autism candidates, both of which use the same delivery tech.

FDA warns that transdermal patch for ADHD can lead to permanent skin discoloration

The FDA warned that a transdermal patch used to treat ADHD in children and adolescents can lead to chemical leukoderma, or permanent skin discoloration, as a result of the skin's repeated exposure to specific chemical compounds.

Alnylam's hemophilia candidate reduces levels of anticoagulant in PhI study

RNAi specialist Alnylam said that development of its early-stage subcutaneous compound for hemophilia and rare bleeding will be accelerated following ongoing Phase I trial results, which indicated that the candidate can knock down levels of the anticoagulant known as antithrombin by up to 86%. Pivotal trials for FDA approval are slated to begin in mid-2016.

Singapore team develops slow-release hydrogel with hep C potential

Hydrogels are known to give drugs an edge when it comes to quick deliverability and simple application, but their long-term efficacy has come into question as their release rates are difficult to control. Researchers in Singapore have developed a new kind of hydrogel that prevents this premature release and allows for fewer doses in patients with chronic diseases like hepatitis C.


From Our Sister Sites


The Washington Post took a swing at medical device association AdvaMed, saying its often-cited claim that more than 30,000 jobs were lost in the U.S. due to the 2.3% excise tax on medical devices contains significant factual errors or obvious contradictions or both.


Ethicon, the Johnson & Johnson unit devoted to surgical tools, is moving to defend its bariatric surgery territory as a slew of noninvasive medical devices to treat obesity line up to gain approval in the U.S. It will spend $3.2 million on more than 20 clinical trials to examine how early surgical intervention can be used to improve conditions such as obesity and Type 2 diabetes.